Baidu
map

JCI:黑色素瘤转移有关的血氧调控因子SRC蛋白被发现

2013-05-06 生物无忧 生物无忧

北卡罗来纳大学的研究人员已经发现了,2个可以调节血液中氧气水平的转录因子也在一种皮肤癌”黑色素瘤”的扩散过程中发挥一定作用. 这项研究的结果被发表在4月8日的Journal of Clinical Investigation上.由北卡罗来纳大学莱恩伯格综合癌症中心的成员William Kim博士领导的研究团队研究了黑色素瘤与一对转录因子HIF1和HIF2之间的联系.这篇文章的第一作者是Kim实验

北卡罗来纳大学的研究人员已经发现了,2个可以调节血液中氧气水平的转录因子也在一种皮肤癌”黑色素瘤”的扩散过程中发挥一定作用.

这项研究的结果被发表在4月8日的Journal of Clinical Investigation上.由北卡罗来纳大学莱恩伯格综合癌症中心的成员William Kim博士领导的研究团队研究了黑色素瘤与一对转录因子HIF1和HIF2之间的联系.这篇文章的第一作者是Kim实验室的研究生Sara Hanna.

研究人员发现,黑色素瘤中的HIF1和HIF2是过表达的.在健康的细胞中,当血液中的氧气水平很低时,HIF1和HIF2能够帮助调节这种低氧的状态.一些类型的实体肿瘤的转移常常与血液中的低氧状态有关.现在,UNC的这一研究团队已经发现了,低氧状态促进了黑色素瘤的扩散,使癌细胞从皮肤顺着淋巴系统到达了身体内的其它位置.

如果一个人被诊断出患有早期的黑色素瘤,那么他的生存率还是很高的,但是一旦这种肿瘤沿着身体扩散到了其他位置,就会造成严重的预后恶化.利用体外实验和小鼠模型,研究者们观察了: 当黑色素瘤中HIF1和HIF2的表达被抑制之后发生了何种现象.他们发现,这两个转录因子的失活并没有降低初始肿瘤的生长,而是降低了黑色素瘤向其他组织的扩散率.

HIF1和HIF2通过不同的信号通路独立地激活了蛋白激酶SRC,SRC蛋白与多种不同癌症的发生发展有关.对它在黑色素瘤中的功能的研究结果暗示,现有的可靶向SRC的治疗或许可以作为一个切实可行的方法来减少癌症的扩散和最终的杀伤力.

Hanna说:“我们未来将要研究的是,当用药物抑制了小鼠模型中的这些信号通路后,癌细胞的转移是否会真的减少.”

黑色素瘤相关的拓展阅读:

doi:10.1172/JCI66715
PMC:
PMID:

HIF1α and HIF2α independently activate SRC to promote melanoma metastases

Sara C. Hanna1, Bhavani Krishnan1, Sean T. Bailey1, Stergios J. Moschos1, Pei-Fen Kuan1,2, Takeshi Shimamura3, Lukas D. Osborne4, Marni B. Siegel1, Lyn M. Duncan5, E. Tim O’Brien, III4, Richard Superfine4, C. Ryan Miller1,6, M. Celeste Simon7, Kwok-Kin Wong8,9 and William Y. Kim1

Malignant melanoma is characterized by a propensity for early lymphatic and hematogenous spread. The hypoxia-inducible factor (HIF) family of transcription factors is upregulated in melanoma by key oncogenic drivers. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the genes involved in the breakdown of the ECM as well as genes that control motility and adhesion of tumor cells. Using a Pten-deficient, Braf-mutant genetically engineered mouse model of melanoma, we demonstrated that inactivation of HIF1α or HIF2α abrogates metastasis without affecting primary tumor formation. HIF1α and HIF2α drive melanoma invasion and invadopodia formation through PDGFRα and focal adhesion kinase–mediated (FAK-mediated) activation of SRC and by coordinating ECM degradation via MT1-MMP and MMP2 expression. These results establish the importance of HIFs in melanoma progression and demonstrate that HIF1α and HIF2α activate independent transcriptional programs that promote metastasis by coordinately regulating cell invasion and ECM remodeling.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981968, encodeId=b9881981968c2, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 18 13:57:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680224, encodeId=36bf168022484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 14 17:57:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668769, encodeId=b6001668e695b, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Sun Jul 21 19:57:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548685, encodeId=18cf154868582, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558640, encodeId=d2bd1558640c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564649, encodeId=6451156464913, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981968, encodeId=b9881981968c2, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 18 13:57:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680224, encodeId=36bf168022484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 14 17:57:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668769, encodeId=b6001668e695b, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Sun Jul 21 19:57:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548685, encodeId=18cf154868582, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558640, encodeId=d2bd1558640c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564649, encodeId=6451156464913, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-06-14 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981968, encodeId=b9881981968c2, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 18 13:57:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680224, encodeId=36bf168022484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 14 17:57:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668769, encodeId=b6001668e695b, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Sun Jul 21 19:57:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548685, encodeId=18cf154868582, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558640, encodeId=d2bd1558640c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564649, encodeId=6451156464913, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-07-21 zhangxingru
  4. [GetPortalCommentsPageByObjectIdResponse(id=1981968, encodeId=b9881981968c2, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 18 13:57:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680224, encodeId=36bf168022484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 14 17:57:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668769, encodeId=b6001668e695b, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Sun Jul 21 19:57:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548685, encodeId=18cf154868582, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558640, encodeId=d2bd1558640c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564649, encodeId=6451156464913, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1981968, encodeId=b9881981968c2, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 18 13:57:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680224, encodeId=36bf168022484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 14 17:57:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668769, encodeId=b6001668e695b, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Sun Jul 21 19:57:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548685, encodeId=18cf154868582, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558640, encodeId=d2bd1558640c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564649, encodeId=6451156464913, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1981968, encodeId=b9881981968c2, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jun 18 13:57:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680224, encodeId=36bf168022484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 14 17:57:00 CST 2013, time=2013-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668769, encodeId=b6001668e695b, content=<a href='/topic/show?id=2ef9166e565' target=_blank style='color:#2F92EE;'>#SRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16675, encryptionId=2ef9166e565, topicName=SRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7c26414300, createdName=zhangxingru, createdTime=Sun Jul 21 19:57:00 CST 2013, time=2013-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548685, encodeId=18cf154868582, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558640, encodeId=d2bd1558640c1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564649, encodeId=6451156464913, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed May 08 14:57:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]

相关资讯

澳研究出黑色素瘤新疗法

  澳大利亚皇家墨尔本理工大学的研究人员8日说,他们研制的一种肽能杀死黑色素瘤细胞,将来有望以此为基础开发一种专门治疗皮肤癌的乳霜。   研究人员将这种肽(即氨基酸短链)设计成能模仿黏液瘤病毒蛋白质的活动。此前的研究已表明,黏液瘤病毒能杀灭恶性黑色素瘤细胞。研究人员测试了这种肽的有效性,结果显示,它可以杀灭黑色素瘤细胞而不伤害正常的人类皮肤细胞。   恶性黑色素瘤是致死率最高的皮肤癌。“澳大利

JCO:新研究揭示转移性黑色素瘤对威罗菲尼的耐药机制

转移性黑色素瘤对威罗菲尼的耐药机制 在2013年4月8日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)上,发表了美国Vanderbilt-Ingram癌症中心Jeffrey A. Sosman博士等人的一项研究结果,该研究旨在评价BRAF抑制剂威罗菲尼对BRAFV600突变性黑色素瘤的药效作用及体内获得性耐药机制,以期对威罗菲尼的作用机制进行了解,并最终

CANCER RES:致命的皮肤癌如何全身扩散

  弗吉尼亚联邦大学梅西癌症中心的科学家Paul B. Fisher博士1月3号发表在《癌症》杂志上的一项研究表明:在肿瘤新血管的形成过程中,mda-9/syntenin是调节血管生成的关键因子。   这是科学家继成功在实验室试验中消除黑色素瘤转移后,又取得的又一项重要发现:黑色素瘤分化相关基因-9(mda-9/syntenin)导致了转移的恶性黑色素瘤(皮肤癌的扩散)和其他

JNCI:PAK1抑制剂能有效治疗BRAF野生型黑色素瘤患者

在携带有BRAF癌基因突变的黑色素瘤患者中,虽然在应用了威罗菲尼或Dabrafenib之后患者对治疗存在显著反应,但是对于野生型BRAF亚型的黑色素瘤患者而言,仍存在大量未满足的临床治疗需要。为了试图探究上述问题,来自Genentech肿瘤转化部门的M. Haverty等进行了相关研究,并将其研究结果发表在JNCI 3月的在线期刊上。为了探究p21小GTP酶活化激酶1(PAKs)在黑色素瘤患者中所

默沙东黑色素瘤药物Lambrolizumab获FDA“突破性疗法”资格

    黑色素瘤通常与过度暴露于紫外线有关,根据美国国家癌症研究所的数据,2013年美国预期会出现76690新病例,其中9480名患者会因此死亡。    突破性疗法资格的获得使lambrolizumab(代号 MK-3475)引起众人关注,授予lambrolizumab这一资格意味着FDA认可该治疗药物对威胁生命的疾病表现出明显收益,而且

NAT GENET :肥胖基因或是黑色素瘤的风险因素

  一项新研究证实与肥胖和暴饮暴食最密切相关的基因,也可能会增加患恶性黑色素瘤的风险,黑色素瘤是皮肤癌中最致命的一种类型,相关研究发表在Nature Genetics杂志上。   英国利兹大学的癌症研究中心科学家发现,FTO基因(通常称为内含子8)的DNA内存在特定变异体的人可能患黑色素瘤的风险更大。FTO基因(内含子1)不同部位的突变体是已知的肥胖和暴饮暴食最重要的遗传危险因素。

Baidu
map
Baidu
map
Baidu
map